Company: CDT
Filing Date: 2025-07-08
Form Type: DEF 14A
Source: 0001641172-25-018242
Chunk: 70

Company: CDT Equity Inc.
Filing Date: 2025-07-08
Form: DEF 14A
Chunk 70
---
 Secretary at the above address no earlier than April 7, 2026 and no later than May 7, 2026, provided that, if the date of next year’s annual meeting changes by more than 30 days before or more than 60 days after the one-year anniversary of the 2025 Annual Meeting ( i.e., August 5, 2026), such proposals must be received by the Secretary at the above address by not earlier than the close of business on the 120th day before the meeting and not later than the later of (x) the close of business on the 90th day before the meeting or (y) the close of business on the 10th day following the day on which public announcement of the date of the annual meeting was first made by the Company.

To comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than June 6, 2026. Such notice may be mailed to the Secretary at the address above or emailed to info@conduitpharma.com.

<div align='center'>OTHER MATTERS</div>

Our Board is not aware of any other matters that are to be presented for action at the 2025 Annual Meeting. However, if any other matters properly come before the 2025 Annual Meeting, your shares of Common Stock will be voted in accordance with the discretion of the designated proxy holders (who are identified on the enclosed proxy card).

It is important that your shares of Common Stock be represented at the 2025 Annual Meeting, regardless of the number of shares that you hold. You are, therefore, urged to vote by using the Internet as instructed on the Notice of Internet Availability of Proxy Materials or enclosed proxy card or by executing and returning, at your earliest convenience, the enclosed proxy card in the envelope that has also been provided.

| By                               
 Order of the Board of Directors, |
| /s/                              
 Dr. Andrew Regan                 |
| Dr.                              
 Andrew Regan                     |
| Chief                            
 Executive Officer and Director   |
| London,                          
 United Kingdom                   |
| July                             
 8, 2025                          |

| 45 |

Annex A

<div align='center'>CONDUIT PHARMACEUTICALS INC.
AMENDED AND RESTATED
2023 STOCK INCENTIVE PLAN

ARTICLE I.
PURPOSE</div>

The Plan